Halibrell (Ranolazine)

Halibrell (ranolazine) is indicated for the symptomatic management of chronic stable angina in adults.

• Relief of angina episodes in patients with chronic stable angina.
• Adjunct therapy when first‑line antianginal agents (e.g., beta‑blockers, calcium‑channel blockers, nitrates) are insufficient.
• Use in patients who cannot tolerate other antianginal medications.
• Management of angina in patients with documented coronary artery disease.
• Improves exercise tolerance and reduces frequency of angina attacks.

The safety profile of Halibrell reflects the known adverse reactions associated with ranolazine, observed in clinical trials and post‑marketing experience.

Common

• Dizziness or light‑headedness, especially when standing quickly.
• Nausea, constipation, or abdominal discomfort that may be transient.
• Headache, ranging from mild to moderate intensity.
• Palpitations or mild tachycardia observed during dose titration.
• Fatigue or generalized weakness affecting daily activities.
• Dry mouth and occasional diarrhea.

Serious

• Prolongation of the QT interval, which may predispose to ventricular arrhythmias and requires ECG monitoring.
• Severe hypersensitivity reactions such as rash, angioedema, or anaphylaxis that need immediate medical attention.
• Elevated liver enzymes indicating possible hepatic involvement; liver function tests should be monitored periodically.
• Severe hypotension or rare cases of cardiac arrest reported in post‑marketing surveillance.

Clinicians should consider several precautions when prescribing Halibrell to ensure safe use in diverse patient populations.

• Assess baseline ECG for QT interval; avoid use in patients with known prolonged QT.
• Use caution in patients with hepatic impairment; dose adjustment may be required.
• Monitor renal function, especially in those with severe renal insufficiency.
• Avoid concomitant use of strong CYP3A4 inhibitors that can increase ranolazine levels.
• Counsel patients about potential dizziness and advise against operating heavy machinery until they know how the drug affects them.
• Consider drug interactions with antiarrhythmics that also affect cardiac conduction.
• Pregnancy and lactation status should be evaluated, as safety data are limited.

Ranolazine may interact with several medications; awareness of these interactions helps prevent adverse effects or reduced efficacy.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, itraconazole) that markedly increase ranolazine plasma concentrations.
• Concomitant use with other QT‑prolonging agents (e.g., sotalol, amiodarone, certain fluoroquinolones) due to additive risk of arrhythmia.
• Dual anti‑platelet therapy with high‑dose clopidogrel, as it may enhance bleeding risk.

Use with caution

• Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil) may increase ranolazine levels; consider dose reduction.
• CYP2D6 substrates (e.g., metoprolol, tricyclic antidepressants) may have altered metabolism when combined.
• Digoxin: ranolazine can increase digoxin concentrations; monitor serum levels.
• Anticoagulants (e.g., warfarin) may require INR monitoring.